Year partnered with Savant: 2022
Sector: Med-tech
Application: Novel Ophthalmology
Product: Patented glaucoma stent leverages natural anatomical mechanisms for clinically effective and cost-saving solution
Market Size: (Local) ZAR 18.63 billion (Global) USD 800 million
Differentiation: Patented enhancements in Continuously Stirred Tank Reactor (CSTR) technology
Investment Stage: Pre-Seed
Stage: Venture and Grow Locally
Founding Team: Daemon McClunan
LIQID Medical
LIQID Medical (LIQID) stands at the forefront of biotechnology, dedicated to pioneering a new class of glaucoma devices. The company’s unwavering focus lies in the creation of protectable intellectual property and the development of commercially viable solutions that redefine the landscape of glaucoma treatment. With a commitment to innovation, LIQID has positioned itself as a leader in the industry, poised to address the challenges posed by glaucoma through groundbreaking advancements in medical technology.
LIQID holds ten patents that encompass the design and application of their novel devices. These patents, filed and awarded across various global territories, underscore LIQID’s dedication to establishing a robust foundation of intellectual property. By harnessing naturally occurring anatomical mechanisms, LIQID aims to provide unparalleled solutions for glaucoma, a leading cause of global blindness. The company’s pioneering approach is rooted in a profound understanding of the intricacies of glaucoma, positioning LIQID as a trailblazer in the quest for more effective, cost-saving, and quality-of-life enhancing treatments.
Value Proposition
LIQID’s innovative glaucoma devices offer a transformative approach to addressing this prevalent eye disease. Engineered with a focus on leveraging natural anatomical mechanisms, these devices represent more than technological advancements—they embody a commitment to providing clinically effective solutions. LIQID’s patented devices have the potential to revolutionize glaucoma treatment, offering not only hope for improved outcomes but also a significant impact on the global burden of irreversible blindness. With a strategic emphasis on creating devices that are not only clinically effective but also commercially viable, LIQID stands as a beacon of progress in the pursuit of enhanced eye health and well-being.
Team
Dr Daemon McClunan
Dr McClunan completed his specialist training at Groote Schuur Hospital where he was the recipient of the Geoff Howes and Ophthalmic society medals awarded to the highest achieving candidate nationwide. He was later awarded his MMed degree with distinction for research into novel corneal surgery. While acting as CEO for LIQID, Dr McClunan is completing his PhD in glaucoma device development at the University of Cape Town. Additionally, he serves on the executive committee of the South African Glaucoma Society and is an honorary senior lecturer at the University of Cape Town.
